Web26 jul. 2024 · This commitment extends across multiple modalities, including antisense oligonucleotides, as with BIIB080,” said Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen. “Biogen is encouraged by the results of this trial, and we look forward to our continued research in future clinical studies with this promising … WebSr. Research Associate(Core Antisense) at Ionis Pharmaceuticals, Inc. San Diego, California, United States. 101 followers 99 connections. Join to view profile ...
Antisense Inhibition of Prekallikrein to Control Hereditary …
Web1 jun. 2024 · During the virtual American Association for Cancer Research Annual Meeting 2024, held April 10–15, MacLeod presented preclinical findings on ION537. To develop the drug, his team first did pilot in vivo studies showing that subcutaneously injected ASOs depleting YAP1 in two mouse models of HCC caused tumor regression and increased … WebFor more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with our novel antisense technology. csutom bar mounted speaker harley
Antisense oligonucleotides targeting - bioRxiv
WebAntisense oligonucleotides (ASOs) modified with phosphorothioate (PS) linkages and different 2' modifications can be used either as drugs (e.g., to treat homozygous familial … WebAt Ionis, Elaine’s research is focused on understanding the activity of GLP-1 conjugated antisense oligonucleotides in the beta cells of the pancreas. The goal: identifying and advancing new targets for Type 1 and Type 2 diabetes. So, … WebIonis Pharmaceuticals, Inc., is headquartered in Carlsbad, California, with offices in Boston, Massachusetts, and Dublin, Ireland. For more than 30 years, Ionis has been the leader in... csutom cables in arkansas